Boston Scientific plans to break ground soon on a major expansion in Maple Grove, a project that’s up for $1.66 million in ...

March 3, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company ...

Boston Scientific (NYSE:BSX) has agreed to acquire medical device company SoniVie for around $360M upfront payment. As a strategic investor in SoniVie, Boston Scientific currently holds an equity ...

Boston Scientific (NYSE: BSX) is buying into the business of acquisitions. The Marlborough medical device firm has announced its second acquisition thus far in 2025. Boston Scientific Corp. has ...

Boston Scientific has shown high revenue and EPS growth rates in recent years. See why I recommend a hold rating for BSX ...

Using the 2 Stage Free Cash Flow to Equity, Boston Scientific fair value estimate is US$82.69 With US$99.13 share price, Boston Scientific appears to be trading close to its estimated fair value ...

Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ultrasound-based therapy for stubbornly high blood pressure. The acquisition sets up ...

Boston Scientific has agreed to buy the rest of privately held medical-device company SoniVie for an initial $360 million in a deal that expands its portfolio of interventional cardiology therapies.

After the sale of its atrial fibrillation-focused startup to Boston Scientific earlier this year, Ajax Health and KKR are teaming up with the medtech once more to launch a new venture aimed at ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire SoniVie, a privately held medical device company that has developed the Tivus Intravascular Ultrasound System.

(RTTNews) - Boston Scientific Corp. (BSX), Monday announced its decision to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System.